Aficamten, a first-in-class cardiac myosin inhibitor, offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed ...
The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...
MyoRegulator, a device to be used at home to slow disability progression in ALS, has been granted breakthrough device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback